With 30 years in practice, Dr. Daniel Howard, a General Surgeon at Mercy Health — Lourdes Hospital, can still define exactly what attracted him to surgery. Dr. Howard’s practice at Mercy Health is the only facility in the state of Kentucky to take advantage of MarginProbe, and it’s leading the state, and the nation, in many other areas of breast cancer treatment.
As part of their whole-person care strategy, Dr. Wilson’s practice uses a new tool, known as MarginProbe, to ensure that a safe margin of tissue is removed around a cancerous tumor as that tumor is removed during surgery.
“I think for breast cancer, every few months there’s something new and exciting,” the physician shared. “I think there’s always some new technology, new drugs, or new study that comes out that changes our outlook.”
“I realized breast surgery put me in the operating room, which I love to do, but it also allowed me to take care of my patients hands-on and I could follow my patients practically forever,” explained Dr. Karen Karsif.
There has been much recent discussion around breast cancer in areas of breast density in relation to detection, and the latest observations in the field of genetics. A veteran breast surgeon, Dr. Erica Giblin, took some time to share her thoughts on the impact of both.
Tidelands Health Breast Center uses the latest technological developments, such as MarginProbe, to refine and improve their surgical outcomes.
Dr. Daniel Barnas shares his thoughts here on how to build and nurture strong patient relationships while ensuring the best physical and cosmetic outcomes throughout the breast cancer treatment journey.
Dr. Alice Police has been a surgeon for 30 years and is a pioneer in her field, having founded her own breast treatment center and currently holding the position of Regional Director of Breast Surgery for Northwell Health in Westchester County, NY.
Dr. Beth Anglin is a breast cancer surgeon with almost 20 years of experience and a unique expertise on the genes responsible for many breast cancer cases: BRCA1 and BRCA2. These are the most common genes involved in hereditary breast and ovarian cancers, and the surgeon recently related that out of the 275-300 breast cancer patients she treats annually, she is currently following 200 that all tested positive for the BRCA gene.
Dr. Jennifer Simmons has a very personal connection to breast cancer – a family member was diagnosed at only 29 years old, dying from the disease at 36. “Breast cancer was very much a part of my childhood and I understood at a very early age the impact that it has on a woman, her family, and the community as a whole. So fighting this disease really resonates with me.”